PL2920168T3 - Heterocykliczne inhibitory glutaminazy - Google Patents

Heterocykliczne inhibitory glutaminazy

Info

Publication number
PL2920168T3
PL2920168T3 PL13855039T PL13855039T PL2920168T3 PL 2920168 T3 PL2920168 T3 PL 2920168T3 PL 13855039 T PL13855039 T PL 13855039T PL 13855039 T PL13855039 T PL 13855039T PL 2920168 T3 PL2920168 T3 PL 2920168T3
Authority
PL
Poland
Prior art keywords
heterocyclic
glutaminase inhibitors
glutaminase
inhibitors
heterocyclic glutaminase
Prior art date
Application number
PL13855039T
Other languages
English (en)
Inventor
Jim Li
Lijing Chen
Bindu Goyal
Guy Laidig
Timothy Friend Stanton
Eric Brian Sjogren
Original Assignee
Calithera Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences, Inc. filed Critical Calithera Biosciences, Inc.
Publication of PL2920168T3 publication Critical patent/PL2920168T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13855039T 2012-11-16 2013-11-15 Heterocykliczne inhibitory glutaminazy PL2920168T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261727195P 2012-11-16 2012-11-16
US201361824434P 2013-05-17 2013-05-17
PCT/US2013/070277 WO2014078645A1 (en) 2012-11-16 2013-11-15 Heterocyclic glutaminase inhibitors
EP13855039.7A EP2920168B1 (en) 2012-11-16 2013-11-15 Heterocyclic glutaminase inhibitors

Publications (1)

Publication Number Publication Date
PL2920168T3 true PL2920168T3 (pl) 2022-01-03

Family

ID=50731715

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13855039T PL2920168T3 (pl) 2012-11-16 2013-11-15 Heterocykliczne inhibitory glutaminazy

Country Status (25)

Country Link
US (2) US10793535B2 (pl)
EP (2) EP2920168B1 (pl)
JP (1) JP6275153B2 (pl)
KR (1) KR102220175B1 (pl)
CN (1) CN105051041B (pl)
AU (1) AU2013344560B2 (pl)
BR (1) BR112015010955A2 (pl)
CA (1) CA2891667A1 (pl)
CY (1) CY1125279T1 (pl)
DK (1) DK2920168T3 (pl)
EA (1) EA029707B1 (pl)
ES (1) ES2899461T3 (pl)
HR (1) HRP20211610T1 (pl)
HU (1) HUE056078T2 (pl)
IL (1) IL238787A0 (pl)
LT (1) LT2920168T (pl)
MX (1) MX381260B (pl)
PL (1) PL2920168T3 (pl)
PT (1) PT2920168T (pl)
RS (1) RS62447B1 (pl)
SG (1) SG11201503720SA (pl)
SI (1) SI2920168T1 (pl)
SM (1) SMT202100589T1 (pl)
WO (1) WO2014078645A1 (pl)
ZA (2) ZA201504294B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
MX381260B (es) 2012-11-16 2025-03-12 Calithera Biosciences Inc Inhibidores heterociclicos de glutaminasa.
SG11201504184PA (en) * 2012-12-03 2015-06-29 Calithera Biosciences Inc Treatment of cancer with heterocyclic inhibitors of glutaminase
CA2934702A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Inhibitors of glutaminase
MX2016014143A (es) * 2014-04-30 2017-02-15 Pfizer Derivados de diheterociclo enlazado a cicloalquilo.
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN107027291B (zh) * 2014-06-13 2020-10-30 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
ES2921989T3 (es) * 2014-07-03 2022-09-05 Univ Texas Terapia con inhibidores de glutaminasa
LT3164394T (lt) 2014-07-03 2020-05-25 Board Of Regents, The University Of Texas System Gls1 inhibitoriai, skirti ligų gydymui
US20160002248A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating disease
WO2016007647A1 (en) 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
BR112017002403A2 (pt) * 2014-08-07 2017-12-05 Calithera Biosciences Inc formas de cristais de inibidores de glutaminase
KR20170131650A (ko) * 2015-03-30 2017-11-29 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제의 투여 방법
CA2981762A1 (en) 2015-04-06 2016-10-13 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
ES2794868T3 (es) 2015-06-30 2020-11-19 Univ Texas Inhibidores de GLS1 para el tratamiento de enfermedades
CA3000996A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10150753B2 (en) 2015-12-22 2018-12-11 Board Of Regents, The University Of Texas System Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
KR20190040302A (ko) * 2016-08-25 2019-04-17 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제와의 병용 요법
WO2018039441A1 (en) * 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US20180055825A1 (en) * 2016-08-25 2018-03-01 Yu Liang Treatment of cancer with inhibitors of glutaminase
JP7275053B2 (ja) * 2017-06-13 2023-05-17 メッドシャイン ディスカバリー インコーポレイテッド Ｇｌｓ１阻害剤としての化合物
EP3697764B1 (en) 2017-10-18 2025-06-11 Board Of Regents, The University Of Texas System Gls-1 inhibitors for use in the treatment of cancer
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN114805346A (zh) * 2021-07-08 2022-07-29 成都硕德药业有限公司 杂环类衍生物、其制备方法及用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
KR100507984B1 (ko) 1997-07-29 2005-08-17 알콘 래보레이토리스, 인코퍼레이티드 갈락토만난 중합체 및 붕산염을 함유하는 안과용 조성물
US6310093B1 (en) 1997-08-29 2001-10-30 Elan Pharmaceuticals, Inc. Method of preventing neuronal death
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
ES2593113T3 (es) 2003-08-07 2016-12-05 Allergan, Inc. Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP4885122B2 (ja) 2004-04-15 2012-02-29 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 癌、器官傷害、および筋肉リハビリテーション／運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US20110281234A1 (en) 2010-05-12 2011-11-17 Colton Crane System and methods for removing a loose tooth
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
EP3620162A1 (en) * 2011-11-21 2020-03-11 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
MX381260B (es) 2012-11-16 2025-03-12 Calithera Biosciences Inc Inhibidores heterociclicos de glutaminasa.
EA029531B1 (ru) 2012-11-21 2018-04-30 Аджиос Фармасьютикалз, Инк. Соединения, ингибирующие глутаминазу, и содержащие эти соединения фармацевтические композиции и их применение
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
SG11201504184PA (en) 2012-12-03 2015-06-29 Calithera Biosciences Inc Treatment of cancer with heterocyclic inhibitors of glutaminase
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
WO2015138902A1 (en) 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN107027291B (zh) 2014-06-13 2020-10-30 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
BR112017002403A2 (pt) 2014-08-07 2017-12-05 Calithera Biosciences Inc formas de cristais de inibidores de glutaminase
KR20170131650A (ko) 2015-03-30 2017-11-29 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제의 투여 방법
CA2981762A1 (en) 2015-04-06 2016-10-13 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
CA3000996A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
KR20190040302A (ko) 2016-08-25 2019-04-17 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제와의 병용 요법
KR20190125432A (ko) 2017-03-10 2019-11-06 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제를 사용하는 병용 요법

Also Published As

Publication number Publication date
EP2920168B1 (en) 2021-07-21
EA029707B1 (ru) 2018-05-31
HK1215023A1 (zh) 2016-08-12
RS62447B1 (sr) 2021-11-30
PT2920168T (pt) 2021-10-18
JP2016505526A (ja) 2016-02-25
EP3954686A1 (en) 2022-02-16
SG11201503720SA (en) 2015-06-29
MX2015005963A (es) 2015-09-16
BR112015010955A2 (pt) 2017-07-11
US10793535B2 (en) 2020-10-06
ZA201606590B (en) 2019-04-24
KR20150085053A (ko) 2015-07-22
US20210292289A1 (en) 2021-09-23
SMT202100589T1 (it) 2021-11-12
LT2920168T (lt) 2021-10-25
IL238787A0 (en) 2015-06-30
ZA201504294B (en) 2018-12-19
HRP20211610T1 (hr) 2022-02-04
WO2014078645A1 (en) 2014-05-22
CN105051041A (zh) 2015-11-11
ES2899461T3 (es) 2022-03-11
MX381260B (es) 2025-03-12
EP2920168A1 (en) 2015-09-23
CN105051041B (zh) 2018-03-30
JP6275153B2 (ja) 2018-02-07
SI2920168T1 (sl) 2022-01-31
EP2920168A4 (en) 2016-04-20
KR102220175B1 (ko) 2021-02-24
EA201590941A1 (ru) 2016-02-29
HUE056078T2 (hu) 2022-01-28
US20140194421A1 (en) 2014-07-10
CY1125279T1 (el) 2023-03-24
CA2891667A1 (en) 2014-05-22
DK2920168T3 (da) 2021-10-18
AU2013344560B2 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
ZA201606590B (en) Heterocyclic glutaminase inhibitors
IL259958B (en) Heterocyclic glutaminase inhibitors
ZA201504200B (en) Beta-lactamase inhibitors
SMT201800669T1 (it) Inibitori di prmt5 e loro usi
AP4029A (en) Inhibitors of beta-secretase
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
IL235919A0 (en) inhibitors of fbxo3
EP2885291A4 (en) INHIBITORS OF VEGFR3
IL236963A0 (en) beta-secretase inhibitors
EP2885292A4 (en) VEGFR3 INHIBITORS
GB201223308D0 (en) Enzyme inhibitors